Literature DB >> 6610061

Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity.

J B Konopka, R L Davis, S M Watanabe, A S Ponticelli, L Schiff-Maker, N Rosenberg, O N Witte.   

Abstract

Antisera specific for six regions of the v- abl protein were used to serologically characterize the Abelson murine leukemia virus tyrosine kinase. Chemically synthesized peptides corresponding to the predicted v- abl protein sequence and larger regions of the v- abl protein expressed as fusion proteins in bacteria were used as immunogens. The specificity of each antiserum was confirmed by immunoprecipitation analysis with defined deletion mutants of Abelson murine leukemia virus. Several of these v- abl -specific antisera display much higher titers and avidities than serum harvested from mice bearing Abelson murine leukemia virus-induced tumors, previously the only source of anti- abl -specific serum. Two antisera were found to block the in vitro autophosphorylation of the v- abl protein as well as its ability to phosphorylate a peptide substrate. Examination of the sites against which the kinase-blocking antisera were prepared revealed that both are in close proximity to the in vivo sites of tyrosine phosphorylation, which fall within the region of high homology with v-src and other tyrosine kinases. Antisera directed against other regions of v- abl did not inhibit kinase activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6610061      PMCID: PMC254421     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  55 in total

1.  Structure of the Abelson murine leukemia virus genome.

Authors:  A Shields; S Goff; M Paskind; G Otto; D Baltimore
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

2.  Evidence that the avian sarcoma virus transforming gene product is a cyclic AMP-independent protein kinase.

Authors:  R L Erikson; M S Collett; E Erikson; A F Purchio
Journal:  Proc Natl Acad Sci U S A       Date:  1979-12       Impact factor: 11.205

3.  A normal cell protein cross-reactive to the major Abelson murine leukaemia virus gene product.

Authors:  O N Witte; N E Rosenberg; D Baltimore
Journal:  Nature       Date:  1979-10-04       Impact factor: 49.962

4.  Extraction of nucleic acids from agarose gels.

Authors:  J Langridge; P Langridge; P L Bergquist
Journal:  Anal Biochem       Date:  1980-04       Impact factor: 3.365

5.  Fluorographic detection of radioactivity in polyacrylamide gels with the water-soluble fluor, sodium salicylate.

Authors:  J P Chamberlain
Journal:  Anal Biochem       Date:  1979-09-15       Impact factor: 3.365

6.  Oncogenes.

Authors:  J M Bishop
Journal:  Sci Am       Date:  1982-03       Impact factor: 2.142

7.  Transforming gene product of Rous sarcoma virus phosphorylates tyrosine.

Authors:  T Hunter; B M Sefton
Journal:  Proc Natl Acad Sci U S A       Date:  1980-03       Impact factor: 11.205

8.  Abelson murine leukemia virus transformation-defective mutants with impaired P120-associated protein kinase activity.

Authors:  F H Reynolds; W J Van de Ven; J R Stephenson
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

9.  Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine.

Authors:  O N Witte; A Dasgupta; D Baltimore
Journal:  Nature       Date:  1980-02-28       Impact factor: 49.962

10.  Identification of phosphotyrosine as a product of epidermal growth factor-activated protein kinase in A-431 cell membranes.

Authors:  H Ushiro; S Cohen
Journal:  J Biol Chem       Date:  1980-09-25       Impact factor: 5.157

View more
  38 in total

1.  Point mutations in the abl SH2 domain coordinately impair phosphotyrosine binding in vitro and transforming activity in vivo.

Authors:  B J Mayer; P K Jackson; R A Van Etten; D Baltimore
Journal:  Mol Cell Biol       Date:  1992-02       Impact factor: 4.272

2.  Insertional mutagenesis of the Abelson murine leukemia virus genome: identification of mutants with altered kinase activity and defective transformation ability.

Authors:  R W Rees-Jones; S P Goff
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

3.  Monoclonal antibodies to gp110 and gp41 of human immunodeficiency virus.

Authors:  L H Gosting; J McClure; E S Dickinson; S M Watanabe; K Shriver; L C Goldstein
Journal:  J Clin Microbiol       Date:  1987-05       Impact factor: 5.948

4.  The 5' noncoding region of the human leukemia-associated oncogene BCR/ABL is a potent inhibitor of in vitro translation.

Authors:  A J Muller; O N Witte
Journal:  Mol Cell Biol       Date:  1989-11       Impact factor: 4.272

5.  Use of site-specific antipeptide antibodies to perturb the serine kinase catalytic activity of p37mos.

Authors:  S A Maxwell; R B Arlinghaus
Journal:  J Virol       Date:  1985-09       Impact factor: 5.103

6.  Expression of the mammalian c-fes protein in hematopoietic cells and identification of a distinct fes-related protein.

Authors:  I MacDonald; J Levy; T Pawson
Journal:  Mol Cell Biol       Date:  1985-10       Impact factor: 4.272

7.  Selective transformation of primitive lymphoid cells by the BCR/ABL oncogene expressed in long-term lymphoid or myeloid cultures.

Authors:  J C Young; O N Witte
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

8.  Subcellular localization of Bcr, Abl, and Bcr-Abl proteins in normal and leukemic cells and correlation of expression with myeloid differentiation.

Authors:  M Wetzler; M Talpaz; R A Van Etten; C Hirsh-Ginsberg; M Beran; R Kurzrock
Journal:  J Clin Invest       Date:  1993-10       Impact factor: 14.808

9.  Mutagenic analysis of the roles of SH2 and SH3 domains in regulation of the Abl tyrosine kinase.

Authors:  B J Mayer; D Baltimore
Journal:  Mol Cell Biol       Date:  1994-05       Impact factor: 4.272

10.  A limited set of SH2 domains binds BCR through a high-affinity phosphotyrosine-independent interaction.

Authors:  A J Muller; A M Pendergast; M H Havlik; L Puil; T Pawson; O N Witte
Journal:  Mol Cell Biol       Date:  1992-11       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.